Lixudebart

DB19244InvestigationalProtein Based Therapies

Lixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.

Mechanism
Curator reviewed
Code names
ALE.F02

Resolves to

Compound
UNIISTN3UZ6YBJCAS2749515-10-2
Targets
O95832CLDN1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lixudebart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In